Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 4,386 | 5,233 | 5,382 | 5,010 | 5,440 | 6,068 | 6,675 | 6,798 |
| Operating profit | $m | 1,636 | 1,704 | ||||||
| Net profit | $m | 823 | 1,503 | 1,522 | 1,402 | 4,175 | 1,074 | 1,021 | 1,767 |
| EPS reported | $ | 1.83 | 1.77 | ||||||
| Operating cashflow per share | $ | 2.73 | 2.98 | ||||||
| Capex per share | $ | 0.44 | 0.51 | ||||||
| FCF per share | $ | 2.28 | 2.47 | ||||||
| Free cash flow | $m | 1,335 | 1,424 | ||||||
| Net debt | $m | -3,604 | -4,046 | ||||||
| Book value equity | $m | 10,338 | 10,861 | ||||||
| Book value per share | $ | 17.65 | 18.80 | ||||||
| Number of shares | m | 585.8 | 577.6 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 46.58 | 59.78 | ||||||
| P/B LTM | x | 4.82 | 5.60 | ||||||
| P/S LTM | x | 8.22 | 9.12 | ||||||
| P/FCF LTM | x | 37.34 | 42.72 | ||||||
| EV/EBITDA LTM | x | 33.31 | 35.42 | ||||||
| EV/Sales LTM | x | 7.85 | 8.51 | ||||||
| Earnings Yield LTM | % | 2.15% | 1.67% | ||||||
| FCF Yield | % | 2.68% | 2.34% | ||||||
| Quality | |||||||||
| ROE | % | 10.38% | 9.69% | ||||||
| ROIC | % | 11.40% | 9.33% | ||||||
| Operating margin | % | 26.97% | 25.52% | ||||||
| Gross margin | % | 78.13% | 78.13% | ||||||
| FCF/Sales | % | 22.00% | 21.34% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -73.74% | -23.71% | ||||||
| Sales Growth YoY | % | +11.55% | +13.44% | ||||||
| Net Income Growth YoY | % | -74.28% | -25.15% | ||||||
| FCF Growth | % | +360.50% | +77.08% | ||||||
| Operating Profit Growth | % | +18.68% | +8.97% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 1.89 | 2.02 | ||||||
| Net Debt/EBITDA | x | -1.56 | -1.50 | ||||||
| EBIT/Net interest | x | - | - | ||||||
| Net debt/market cap | % | -7.23% | -6.65% | ||||||
| Net debt/Equity | x | -0.35 | -0.37 | ||||||
| Gross debt/equity | x | 0.07 | 0.06 | ||||||
ETFs that hold Edwards Lifesciences
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Russell Mid-Cap Value ETF | IWS | 8 | 0.57% |
| iShares U.S. Medical Devices ETF | IHI | 5 | 4.78% |
| Avantis U.S. Mid Cap Equity ETF | AVMC | 6 | 0.56% |
| iShares US Medical Devices UCITS ETF USD | UMDV.AS | 7 | 5.24% |
| Virtus Terranova U.S. Quality Momentum ETF | JOET | 4 | 0.93% |
| State Street SPDR S&P Health Care Equipment ETF | XHE | 10 | 1.76% |
| Calvert US Mid-Cap Core Responsible Index ETF | CVMC | 8 | 0.54% |
| Global X - Aging Population ETF | AGNG | 4 | 3.49% |
Funds with Edwards Lifesciences among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Edwards Lifesciences Corporation (EW)
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Russell Mid-Cap Value ETF | IWS | 8 | 0.57% |
| iShares U.S. Medical Devices ETF | IHI | 5 | 4.78% |
| Avantis U.S. Mid Cap Equity ETF | AVMC | 6 | 0.56% |
| iShares US Medical Devices UCITS ETF USD | UMDV.AS | 7 | 5.24% |
| Virtus Terranova U.S. Quality Momentum ETF | JOET | 4 | 0.93% |
| State Street SPDR S&P Health Care Equipment ETF | XHE | 10 | 1.76% |
| Calvert US Mid-Cap Core Responsible Index ETF | CVMC | 8 | 0.54% |
| Global X - Aging Population ETF | AGNG | 4 | 3.49% |
Funds with Edwards Lifesciences among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free